Toria Nino, Kikodze Nino, Janikashvili Nona, Pantsulaia Ia, Mizandari Malkhaz, Chikovani Tinatin, Habib Nagy
Department of Immunology, Tbilisi State Medical University, 33 Vazha-Pshavela Ave, Tbilisi, 0186, Georgia.
V. Bakhutashvili Institute of Medical Biotechnology, Tbilisi State Medical University, Tbilisi, Georgia.
Radiol Case Rep. 2022 Jul 29;17(10):3607-3610. doi: 10.1016/j.radcr.2022.07.017. eCollection 2022 Oct.
Radiofrequency ablation (RFA) has widespread popularity due to its immune-modulation effects in many cancers. Optimal settings to apply RFA in pancreatic cancer, in which the advanced stage of the tumor at the diagnosis makes various therapeutic approaches fail, are still demanding. We report the case of a patient with unresectable pancreatic cancer in which 3 repetitive RFA has been applied over a period of 3 months. Results revealed an improvement in the patient's clinical condition associated with the reduced incidence of CD4+CD45RO+ T lymphocytes and declined TGF-β level in serum. The good quality of life and disease-free survival were maintained for the next months. Booster application of RFA procedure might be a promising option to improve the quality of life in pancreatic cancer patients.
射频消融术（RFA）因其在多种癌症中的免疫调节作用而广受欢迎。在胰腺癌中应用RFA的最佳设置仍有待确定，因为胰腺癌在诊断时处于晚期，使得各种治疗方法均告失败。我们报告了一例不可切除胰腺癌患者的病例，该患者在3个月内接受了3次重复RFA治疗。结果显示，患者的临床状况有所改善，同时血清中CD4+CD45RO+ T淋巴细胞的发生率降低，转化生长因子-β水平下降。在接下来的几个月里，患者保持了良好的生活质量和无病生存期。再次应用RFA治疗可能是改善胰腺癌患者生活质量的一个有前景的选择。
